Landmark victory for individuals living with DEB and their families, the FDA announced their approval of Krystal Biotech’s VYJUVEK™ for the treatment of Dystrophic Epidermolysis Bullosa (DEB).

Investors look past US tech sector as uncertain environment clouds outlook

Mexican peso to stay strong despite end of cenbank tightening cycle - analysts

Eternal space division wins NASA competition

Man Group’s Trailblazing CEO Aims to Keep Firm’s Momentum

Pay Transparency Laws: What Small Businesses Need to Know

'ESG' in U.S. finance job titles comes with 20% pay premium

The Best Pet Workplaces Offer Bereavement and Pawternity Leave

Timeline of Brazil's inflation target to be discussed with Lula, says finance minister

Kia/Hyundia settle class-action lawsuit over security flaw in vehicles

Saudi Fund for Development Signs a Multiyear Contribution Agreement With the Global Fund

Disney's fight with DeSantis masks a bigger problem: Its business is struggling